Literature DB >> 7533607

A murine model of cystic fibrosis.

J N Snouwaert1, K K Brigman, A M Latour, E Iraj, U Schwab, M I Gilmour, B H Koller.   

Abstract

We have generated a mouse line in which the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been mutated by gene targeting. Like human cystic fibrosis (CF) patients, mice lacking a functional CFTR gene, referred to as CFTR(-/-) mice, show increased numbers of goblet cells and obstruction of glands with inspissated eosinophilic secretions. The obstruction of glands often results in the destruction of gland-containing tissues in these animals. However, unlike the case in human CF patients, the most severe pathological changes in these mice were found, on preliminary analysis, to be confined to the intestinal tract and gallbladder. Although respiratory failure is the primary cause of death among humans with CF, we found only minor pathological alterations in the lungs and upper airways of our CFTR(-/-) animals. Possible explanations for the apparent lack of respiratory disease are the young age at which the animals were examined and the pathogen-free environment in which they were housed. In this manuscript, we examine the respiratory and other organ systems of CFTR(-/-) mice that have survived to adulthood. We also report on initial experiments in which CFTR(-/-) mice have been exposed to bacterial pathogens, and we present data on a single animal that displayed severe respiratory disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533607     DOI: 10.1164/ajrccm/151.3_Pt_2.S59

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

1.  Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions.

Authors:  J R Davies; N Svitacheva; L Lannefors; R Kornfält; I Carlstedt
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

Review 2.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

3.  Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice.

Authors:  U Sajjan; G Thanassoulis; V Cherapanov; A Lu; C Sjolin; B Steer; Y J Wu; O D Rotstein; G Kent; C McKerlie; J Forstner; G P Downey
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect.

Authors:  G Wang; V Slepushkin; J Zabner; S Keshavjee; J C Johnston; S L Sauter; D J Jolly; T W Dubensky; B L Davidson; P B McCray
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

5.  PCR-analyzed microsatellites for the inbred mouse strain 129/Sv, the strain most commonly used in gene knockout technology.

Authors:  C Matouk; D Gosselin; D Malo; E Skamene; D Radzioch
Journal:  Mamm Genome       Date:  1996-08       Impact factor: 2.957

6.  Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis (CF) mouse.

Authors:  S Ghosal; C J Taylor; J McGaw
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

7.  Isolation and long-term culture of gallbladder epithelial cells from wild-type and CF mice.

Authors:  R Kuver; C Savard; T D Nguyen; W R Osborne; S P Lee
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-02       Impact factor: 2.416

Review 8.  Cystic fibrosis-related bone disease: insights into a growing problem.

Authors:  Michael S Stalvey; Gregory A Clines
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-12       Impact factor: 3.243

9.  PATHOPHYSIOLOGIC EVALUATION OF THE TRANSGENIC CFTR "GUT-CORRECTED" PORCINE MODEL OF CYSTIC FIBROSIS.

Authors:  Stephen T Ballard; Jessica W Evans; Holly S Drag; Michele Schuler
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-08-19       Impact factor: 5.464

10.  Porcine vas deferens luminal pH is acutely increased by systemic xylazine administration.

Authors:  Fernando Pierucci-Alves; Cameron L Duncan; James D Lillich; Bruce D Schultz
Journal:  Biol Reprod       Date:  2009-08-14       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.